Summary
GyroGlove is a wearable active device based on miniaturised gyroscopes, designed to suppress the hand tremor commonly
seen in people suffering from Parkinson’s Disease (PD) or Essential Tremor (ET). With the help of Innovate UK Proof of
Concept (PoC) grant we have taken the idea from very early lab simulators through to functional prototypes. These were
tested on PD and ET patients in lab conditions. We were able to demonstrate a 50% reduction in tremor in half of the tests
and as much as 95% in one case. GyroGlove has commenced pre-production development (as of Nov 2017). The team
has achieved TRL 6 as of this application and demonstrated proof-of-concept with group patient tests (30 users). The
GyroGlove form-factor comprises a lightweight/comfortable mount for an enclosed gyroscope which spins at approximately
20,000 RPM. By stabilising the hand directly, the GyroGlove is targeted at multi-function use (eating, drinking, writing, selfcare
etc.) to return independence and freedom to users. Given development and user testing success thus far, the phase 2
project will enable us to: finalise engineering design specification; build functional and pre-production prototypes; transfer to
manufacture; conduct clinical trials and gain regulatory approval; develop supply chain agreements and commercial
contracts ready for full commercialisation and multiple-market entry in Q4 2022 .
seen in people suffering from Parkinson’s Disease (PD) or Essential Tremor (ET). With the help of Innovate UK Proof of
Concept (PoC) grant we have taken the idea from very early lab simulators through to functional prototypes. These were
tested on PD and ET patients in lab conditions. We were able to demonstrate a 50% reduction in tremor in half of the tests
and as much as 95% in one case. GyroGlove has commenced pre-production development (as of Nov 2017). The team
has achieved TRL 6 as of this application and demonstrated proof-of-concept with group patient tests (30 users). The
GyroGlove form-factor comprises a lightweight/comfortable mount for an enclosed gyroscope which spins at approximately
20,000 RPM. By stabilising the hand directly, the GyroGlove is targeted at multi-function use (eating, drinking, writing, selfcare
etc.) to return independence and freedom to users. Given development and user testing success thus far, the phase 2
project will enable us to: finalise engineering design specification; build functional and pre-production prototypes; transfer to
manufacture; conduct clinical trials and gain regulatory approval; develop supply chain agreements and commercial
contracts ready for full commercialisation and multiple-market entry in Q4 2022 .
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/830457 |
| Start date: | 01-09-2018 |
| End date: | 31-08-2022 |
| Total budget - Public funding: | 2 653 197,00 Euro - 1 857 238,00 Euro |
Cordis data
Original description
GyroGlove is a wearable active device based on miniaturised gyroscopes, designed to suppress the hand tremor commonlyseen in people suffering from Parkinson’s Disease (PD) or Essential Tremor (ET). With the help of Innovate UK Proof of
Concept (PoC) grant we have taken the idea from very early lab simulators through to functional prototypes. These were
tested on PD and ET patients in lab conditions. We were able to demonstrate a 50% reduction in tremor in half of the tests
and as much as 95% in one case. GyroGlove has commenced pre-production development (as of Nov 2017). The team
has achieved TRL 6 as of this application and demonstrated proof-of-concept with group patient tests (30 users). The
GyroGlove form-factor comprises a lightweight/comfortable mount for an enclosed gyroscope which spins at approximately
20,000 RPM. By stabilising the hand directly, the GyroGlove is targeted at multi-function use (eating, drinking, writing, selfcare
etc.) to return independence and freedom to users. Given development and user testing success thus far, the phase 2
project will enable us to: finalise engineering design specification; build functional and pre-production prototypes; transfer to
manufacture; conduct clinical trials and gain regulatory approval; develop supply chain agreements and commercial
contracts ready for full commercialisation and multiple-market entry in Q4 2022 .
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
